Acrivon Therapeutics (ACRV) Stock: Buy, Sell, or Hold?
ACRV - Acrivon Therapeutics, Inc. Common Stock
$2.01
-0.04 (-1.95%)
âŧ
5d:
-5.19%
30d:
-2.9%
90d:
+16.86%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Get Alerted When ACRV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ACRV is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ACRV is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ACRV is currently trading at $2.01, which is considered fair relative to its 30-day fair value range of $1.91 to $2.16.
Technical Outlook: Technically, ACRV is in a uptrend. Immediate support is located at $1.69, while resistance sits at $2.24.
Market Sentiment: ACRV scores 22/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.50 (+472.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ACRV is in a uptrend. Immediate support is located at $1.69, while resistance sits at $2.24.
Market Sentiment: ACRV scores 22/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.50 (+472.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.91 -
$2.16
Company Quality Score
40/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (22/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 472.1% below Wall St target ($11.50)
- WARNING: Composite score 40/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.91 -
$2.16
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.69
Resistance Level
$2.24
Current Trend
Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.22
Wall Street Target
$11.50
(+472.1%)
Share & Embed Analysis
Last updated: October 02, 2026 6:44 AM ET
Data refreshes hourly during market hours. Next update: 7:44 AM
Data refreshes hourly during market hours. Next update: 7:44 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACRV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 51 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$47 | 55 HOLD |
|
REGN
Regeneron PharmaceuticalâĻ |
STRONG BUY
25 analysts |
$851 | 53 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$293 | 61 BUY |
|
MLTX
MoonLake ImmunotherapeutâĻ |
STRONG BUY
16 analysts |
$29 | 51 HOLD |
